Lexicon Pharmaceuticals, Inc. (LXRX)
2.32
+0.02
(+0.87%)
USD |
NASDAQ |
Aug 24, 16:00
2.325
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Enterprise Value : 900.88M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 900.88M |
| August 21, 2026 | 891.99M |
| August 20, 2026 | 838.59M |
| August 19, 2026 | 940.93M |
| August 18, 2026 | 945.38M |
| August 17, 2026 | 909.78M |
| August 14, 2026 | 900.88M |
| August 13, 2026 | 909.78M |
| August 12, 2026 | 914.23M |
| August 11, 2026 | 949.83M |
| August 10, 2026 | 936.48M |
| August 07, 2026 | 967.63M |
| August 06, 2026 | 918.68M |
| August 05, 2026 | 958.73M |
| August 04, 2026 | 976.52M |
| August 03, 2026 | 905.33M |
| July 31, 2026 | 896.44M |
| July 30, 2026 | 909.78M |
| July 29, 2026 | 900.88M |
| July 28, 2026 | 909.78M |
| July 27, 2026 | 860.84M |
| July 24, 2026 | 887.54M |
| July 23, 2026 | 891.99M |
| July 22, 2026 | 869.74M |
| July 21, 2026 | 927.58M |
| Date | Value |
|---|---|
| July 20, 2026 | 905.33M |
| July 17, 2026 | 932.03M |
| July 16, 2026 | 865.29M |
| July 15, 2026 | 847.49M |
| July 14, 2026 | 811.90M |
| July 13, 2026 | 834.14M |
| July 10, 2026 | 856.39M |
| July 09, 2026 | 869.74M |
| July 08, 2026 | 878.64M |
| July 07, 2026 | 923.13M |
| July 06, 2026 | 900.88M |
| July 02, 2026 | 900.88M |
| July 01, 2026 | 909.78M |
| June 30, 2026 | 936.48M |
| June 29, 2026 | 1.006B |
| June 26, 2026 | 967.68M |
| June 25, 2026 | 857.50M |
| June 24, 2026 | 827.83M |
| June 23, 2026 | 802.41M |
| June 22, 2026 | 798.17M |
| June 18, 2026 | 738.84M |
| June 17, 2026 | 751.55M |
| June 16, 2026 | 713.41M |
| June 15, 2026 | 717.65M |
| June 12, 2026 | 700.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viatris, Inc. | 31.32B |
| Pfizer Inc. | 211.20B |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
| Veru, Inc. | 21.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.78M |
| Revenue (Quarterly) | 0.692M |
| Total Expenses (Quarterly) | 32.47M |
| EPS Diluted (Quarterly) | -0.0726 |
| Gross Profit Margin (Quarterly) | 79.62% |
| Profit Margin (Quarterly) | -4.59K% |
| Earnings Yield | -6.59% |
| Normalized Earnings Yield | -6.297 |